Our recent research supports that CYP monooxygenases could be novel therapeutic targets of CRC [12], and sEH, a down-stream enzyme in the CYP eicosanoid pathway, could be a potential target of obesity-associated CRC [41]. This evidence concerns the gene EPHX2 and obesity disorder.